About Us
Eukarion, Inc. is a privately held biopharmaceutical company dedicated to developing innovative therapeutic agents targeting intracellular mechanisms associated with aging and age-related diseases.
Founded in 1991, our headquarters are in Bedford, MA. Our team of experts collaborates with leading academic institutions to drive breakthrough research toward clinical applications.
Our Mission
To develop proprietary therapeutic agents directed against intracellular targets for aging and age-related diseases.
We are committed to advancing novel solutions that address the biological challenges of aging and disease progression.
Research & Development
Our cutting-edge research focuses on two primary therapeutic strategies
🔬 Synthetic Catalytic Scavengers (SCS): Designed to neutralize harmful reactive oxygen species, which contribute to neurological, cardiovascular, autoimmune, and infectious diseases.
🧬 Lipoclonal® Antibodies: A revolutionary protein modification technology that allows antibodies to cross cellular membranes and target intracellular disease-associated proteins.
Science Overview
✅ SCS – Combating Oxidative Damage
Eukarion's SCS program is aimed at eliminating toxic oxygen radicals and other reactive oxygen species, which are implicated in various diseases. These novel compounds work in animal models by catalytically neutralizing oxidative damage, with therapeutic potential in:
- Neuroprotection: Alzheimer's, Parkinson’s, stroke, and multiple sclerosis.
- Cardiovascular Health: Protecting heart tissue in myocardial infarction.
- Autoimmune & Infectious Diseases: Reducing mortality in systemic lupus erythematosus (SLE) and mitigating allergic inflammation.
✅ Lipoclonal® Antibodies – Targeting Intracellular Diseases
Eukarion's first modified antibody has been engineered to enter cells and disrupt the function of Tat, a key protein required for AIDS virus multiplication. This breakthrough has shown:
- Successful intracellular delivery.
- Effective blocking of target proteins.
- Inhibition of AIDS virus multiplication.
- Protection of infected human cells.
Key Achievements
🏆 Awarded six NIH grants (four Phase 1, two Phase 2) supporting research and development.
đź“ś Holder of multiple patents, with five already issued in the U.S.
đź“– Published extensively in peer-reviewed scientific journals in collaboration with leading researchers.
Let's Connect
This layout ensures a professional, engaging, and informative homepage with clear sections highlighting your company’s mission, research focus, and achievements. Let me know if you need any refinements!